Zacks Investment Research
06 Jul 2026, 15:51 UTC · 2h ago
Will Immunology Franchise Aid AbbVie's Upcoming Q2 Results?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
06 Jul 2026, 15:51 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
AbbVie is expected to report second-quarter 2026 results on July 31, with investors focusing on Skyrizi and Rinvoq sales. — Earnings dates and specific product sales targets are primary catalysts for short-term price volatility in pharmaceutical stocks.
+0.40Skyrizi and Rinvoq are driving AbbVie's return to top-line growth, offsetting the loss of exclusivity for Humira. — Successful product substitution for a legacy blockbuster is a critical indicator of long-term company viability.
+0.30Humira sales are expected to continue a downward trajectory, with estimates pegged at $744 million for the quarter. — The continued decay of a former primary revenue driver acts as a persistent drag on the company's valuation.
-0.20Continue reading
6 related stories
Top 1 mover · tap to explore
AbbVie is diversifying its revenue streams by expanding into oncology (adding drugs like Decnupaz) and neuroscience (Ubrelvy, Qulipta, and Vyalev). — Pipeline diversification reduces risk associated with single-sector dependency (immunology).
+0.20Johnson & Johnson is shifting focus to Tremfya and has secured approval for a new psoriasis drug, Icotyde, following Stelara's patent loss. — New approvals and strategic pivots by a major competitor influence the overall competitive landscape of the immunology market.
+0.10Which stocks this story touches
Company shows strong top-line growth and momentum driven by blockbuster drugs Skyrizi and Rinvoq.
Mentioned as a competitor in the immunology space without a clear positive or negative catalyst provided in the text.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
